keyword
MENU ▼
Read by QxMD icon Read
search

liver trial cancer

keyword
https://www.readbyqxmd.com/read/29334698/endoscopic-ultrasound-and-the-liver-current-applications-and-beyond
#1
REVIEW
Neil D Shah, Todd H Baron
The diagnosis and management of many gastrointestinal conditions has been augmented by the development of endoscopic ultrasound. Its role in the diagnosis and management of liver disease has been somewhat limited, but with the rapid development of therapeutic advancements it has quickly emerged as a useful tool in the management of complex hepatic conditions. This includes its use in the management of complications of portal hypertension as well as its use in liver lesions and cancer. In this paper, we review case studies, case series and trials for hepatic applications of endoscopic ultrasound to provide an overview of its utilization in this field and demonstrating its more novel applications for future use...
January 15, 2018: Journal of Hepato-biliary-pancreatic Sciences
https://www.readbyqxmd.com/read/29334610/phase-ii-study-of-dovitinib-in-patients-with-castration-resistant-prostate-cancer-kcsg-gu11-05
#2
Yoon Ji Choi, Hye Sook Kim, Se Hoon Park, Bong-Seog Kim, Kyoung Ha Kim, Hyo Jin Lee, Hong Suk Song, Dong-Yeop Shin, Ha Young Lee, Hoon-Gu Kim, Kyung Hee Lee, Jae Lyun Lee, Kyong Hwa Park
Purpose: Fibroblast growth factor (FGF) signals are important in carcinogenesis and progression of prostate cancer. Dovitinib is an oral, pan-class inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and fibroblast growth factor receptor (FGFR). We evaluated the efficacy and toxicity of dovitinib in men with metastatic castration resistant prostate cancer (mCRPC). Materials and Methods: This study was a single-arm, phase II, open-label, multicenter trial of dovitinib 500mg/day (5-days-on/2-days-off schedule)...
January 2, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29322091/a-retroviral-replicating-vector-encoding-cytosine-deaminase-and-5-fc-induces-immune-memory-in-metastatic-colorectal-cancer-models
#3
Kader Yagiz, Maria E Rodriguez-Aguirre, Fernando Lopez Espinoza, Tiffany T Montellano, Daniel Mendoza, Leah A Mitchell, Carlos E Ibanez, Noriyuki Kasahara, Harry E Gruber, Douglas J Jolly, Joan M Robbins
Treatment of tumors with Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, followed by 5-fluorocytosine (5-FC) kills tumors by local production of 5-fluorouracil (5-FU). In brain tumor models, this treatment induces systemic anti-tumor immune responses and long-term immune-mediated survival. Phase 1 Toca 511 and Toca FC (extended-release 5-FC) clinical trials in patients with recurrent high-grade glioma show durable complete responses and promising survival data compared to historic controls...
March 30, 2018: Molecular Therapy Oncolytics
https://www.readbyqxmd.com/read/29316037/development-of-a-recombinant-murine-tumor-model-using-hepatoma-cells-expressing-hepatitis-c-virus-hcv-non-structural-antigens
#4
K Young, K Haq, S MacLean, R Dudani, S M Elahi, R Gilbert, R Weeratna, L Krishnan
Hepatitis C virus (HCV) chronically infects 2-3% of the world's population, causing liver disease and cancer with prolonged infection. The narrow host range of the virus, being restricted largely to human hepatocytes, has made the development of a relevant infection and reliable model to evaluate the efficacy of vaccines a challenge. We have developed a novel approach to accomplish this by generating a murine hepatoma cell line stably expressing non-structural HCV antigens which can be used in vitro or in vivo to test HCV vaccine efficacies...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29307930/hepatocyte-specific-contrast-agent-enhanced-magnetic-resonance-cholangiography-perioperative-evaluation-of-the-biliary-tree
#5
Luciana Carmen Zattar-Ramos, Regis Otaviano Franca Bezerra, Luis Tenório de Brito Siqueira, Marcos Roberto Menezes, Claudia da Costa Leite, Giovanni Guido Cerri
A large number of gadolinium chelates have recently been tested in clinical trials. Some of those have already been approved for clinical use in the United States and Europe. Thus, new diagnostic perspectives have been incorporated into magnetic resonance imaging studies. Among such gadolinium chelates are hepatobiliary-specific contrast agents (HSCAs), which, due to their property of being selectively taken up by hepatocytes and excreted by the biliary ducts, have been widely used for the detection and characterization of focal hepatic lesions...
November 2017: Radiologia Brasileira
https://www.readbyqxmd.com/read/29299827/apical-lymph-nodes-in-the-distant-metastases-and-prognosis-of-patients-with-stage-iii-colorectal-cancer-with-adequate-lymph-node-retrieval-following-folfox-adjuvant-chemotherapy
#6
Hsiang-Lin Tsai, Yi-Ting Chen, Yung-Sung Yeh, Ching-Wen Huang, Cheng-Jen Ma, Jaw-Yuan Wang
The aim of the study was to assess apical lymph nodes (APNs) for predicting distant metastases in patients with stage III colorectal cancer (CRC) curatively treated with FOLFOX adjuvant chemotherapy and adequate lymph node retrieval. We investigated the correlation between APN metastasis and clinical outcomes. This retrospective study examined 97 patients. All patients were followed until death, loss to follow-up, or May 2017. Clinicopathological variables, including the APN status, were assessed. Multivariate logistic regression model was used to identify the independent risk factors for APN and distant metastases, and Cox proportional regression model was used to evaluate the association between APN metastasis and oncologic outcomes...
January 3, 2018: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29290261/does-nivolumab-for-progressed-metastatic-lung-cancer-fulfill-its-promises-an-efficacy-and-safety-analysis-in-20-general-hospitals
#7
Kurt G Tournoy, Michiel Thomeer, Paul Germonpré, Sofie Derijcke, Rebecca De Pauw, Daniëlla Galdermans, Karl Govaert, Elke Govaerts, Rob Schildermans, Isabelle Declercq, Nele De Brucker, Karin Pat, Rika Van Herreweghe, Luc Van Zandweghe, Luc Vanmaele, Valerie Van Damme, Heidi Marien, Sofie De Craene, Isabelle Fabry, Patrick Alexander, Piet Vercauter, Ingel Demedts
OBJECTIVES: In patients with refractory or recurrent non-small-cell lung cancer (NSCLC) after first line chemotherapy, phase III trials showed superiority of nivolumab, an IgG4 programmed death-1 immune-checkpoint-inhibitor antibody, over docetaxel. We evaluated case mix, effectiveness and safety of nivolumab upon implementation in general practice. MATERIALS AND METHODS: In 20 general hospitals, all consecutive NSCLC patients treated with nivolumab within the medical need program (inclusion period 12 months) in Flanders - Belgium were evaluated...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29274197/increased-recurrence-rates-of-hepatocellular-carcinoma-after-daa-therapy-in-a-hepatitis-c-infected-egyptian-cohort-a-comparative-analysis
#8
Mohamed El Kassas, Anna L Funk, Mohamed Salaheldin, Yusuke Shimakawa, Mohammed Eltabbakh, Kévin Jean, Adel El Tahan, Ahmad T Sweedy, Shimaa Afify, Naglaa Fa Youssef, Gamal Esmat, Arnaud Fontanet
In Egypt, hepatocellular carcinoma (HCC) is the most common form of cancer and direct acting antivirals (DAA) are administered on a large scale to patients with chronic HCV infection to reduce the risk. In this unique setting, we aimed to determine the association of DAA exposure with early phase HCC recurrence in patients with a history of HCV-related liver cancer. This was a prospective cohort study of an HCV infected population from one Egyptian specialized HCC management center starting from the time of successful HCC intervention...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29262510/-a-prospective-pilot-study-of-combined-intra-operative-radiotherapy-for-centrally-located-hepatocellular-carcinomas
#9
Y H Liu, L M Wang, J X Wu, W Q Rong, F Wu, M H Li, Y Zhang, S T Lin, Y L Zheng, Q F Feng
Objective: To carry out a prospective cohort study of combined intra-operative radiotherapy for centrally located hepatocellular carcinomas (HCC) and to observe the safety and postoperative complications. Methods: A total of 79 patients with centrally located HCC who underwent hepatectomy were divided into two groups: experimental group (combined with targeted intra-operative radiotherapy, 32 cases) and control group (single surgical operation, 47 cases). Patients in the experimental group received intra-operative electron radiotherapy after tumor resection, while patients in the control group received to intra-operative electron radiotherapy...
December 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/29258858/emerging-biomarkers-for-immunomodulatory-cancer-treatment-of-upper-gastrointestinal-pancreatic-and-hepatic-cancers
#10
REVIEW
Belinda Lee, Ryan Hutchinson, Hui-Li Wong, Jeanne Tie, Tracy Putoczki, Ben Tran, Peter Gibbs, Michael Christie
Carcinomas of the oesophagus, stomach, pancreas and liver are common and account for a disproportionately high number of cancer deaths. There is a need for new treatment options for patients with advanced disease. Immunomodulatory treatments including immune checkpoint blockade offer a promising new approach, with efficacy shown in other solid tumour types. However, only a small proportion of patients with carcinomas of the oesophagus, stomach, pancreas and liver have responded to single agent checkpoint inhibitors, and there is a need for markers that are predictive of response to guide treatment of individual patients...
December 16, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29250323/strategies-for-prevention-of-gastrointestinal-cancers-in-developing-countries-a-systematic-review
#11
Ahmad Zia Shams, Ulrike Haug
Background: Gastrointestinal cancers account for one third of total cancer incidence and mortality in developing countries. To date, there is no systematic synthesis of evidence regarding strategies to prevent gastrointestinal cancers in developing countries. We aimed to provide a systematic overview of studies evaluating strategies for prevention or early detection of the three most common gastrointestinal cancers (gastric, liver and colorectal cancer) in developing countries. Methods: We searched MEDLINE, Web of Science and WHO Global Index Medicus databases for relevant articles published until October 2016 using combinations of the search terms "gastrointestinal", "digestive system", "gastric", "liver", "colorectal", "cancer", "prevention", "early detection" and "developing country" (including names)...
December 2017: Journal of Global Health
https://www.readbyqxmd.com/read/29248731/pharmacokinetic-profile-of-pbrm-in-rodents-a-first-selective-covalent-inhibitor-of-17%C3%AE-hsd1-for-breast-cancer-and-endometriosis-treatments
#12
René Maltais, Alexandre Trottier, Jenny Roy, Diana Ayan, Nicolas Bertrand, Donald Poirier
The development of a covalent inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is a promising approach for the treatment of hormone-dependent breast cancer and endometriosis. After reporting the steroid derivative PBRM as a first potent covalent inhibitor of 17β-HSD1 without estrogenic activity, we are now interested in studying its pharmaceutical behavior. The metabolism study in a human liver microsomal preparation showed a gradual transformation of PBRM into PBRM-O, an oxidized ketonic form of PBRM at position C17...
December 14, 2017: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/29246010/the-efficacy-and-safety-of-different-pharmacological-interventions-for-patients-with-advanced-biliary-tract-cancer-a-network-meta-analysis
#13
Xin-Fang Sun, Zhi-Kuan He, Jin-Ping Sun, Quan-Xing Ge, Er-Dong Shen
Biliary tract cancer (BTC) is the second common cancer in liver cancer. Chemotherapy is the mainstay of treatments for patients with advanced or metastatic disease, while fluorouracil (FU)-based and gemcitabine (GEM)-based treatments are most widely applied. This NMA aimed to figure out whether the addition of platinum (PLA) and target agents (TAR) can influence the efficacy and safety of standard chemotherapy. Network meta-analysis (NMA) was conducted based on the records from PubMed, Embase and Cochrane. Eligible data was extracted from available qualified trials and outcomes...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29242381/therapeutic-targeting-of-non-coding-rnas-in-cancer
#14
REVIEW
Ondrej Slaby, Richard Laga, Ondrej Sedlacek
The majority of the human genome encodes RNAs that do not code for proteins. These non-coding RNAs (ncRNAs) affect normal expression of the genes, including oncogenes and tumour suppressive genes, which make them a new class of targets for drug development in cancer. Although microRNAs (miRNAs) are the most studied regulatory ncRNAs to date, and miRNA-targeted therapeutics have already reached clinical development, including the mimics of the tumour suppressive miRNAs miR-34 and miR-16, which reached phase I clinical trials for the treatment of liver cancer and mesothelioma, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognised...
December 14, 2017: Biochemical Journal
https://www.readbyqxmd.com/read/29237358/on-the-relationship-of-anthranilic-derivatives-structure-and-the-fxr-farsenoid-x-receptor-agonist-activity
#15
Thales Kronenberger, Björn Windshügel, Carsten Wrenger, Kathia M Honorio, Vinicius G Maltarollo
Farsenoid X receptor (FXR) is a nuclear receptor related to lipid and glucose homeostasis and is considered an important molecular target to treatment of metabolic diseases as diabetes, dyslipidemia and liver cancer. Nowadays, there are several FXR agonists reported in the literature and some of it in clinical trials for liver disorders. Herein a compound series was employed to generate QSAR models to better understand the structural basis for FXR by anthranilic acid derivatives (AADs) agonists. Furthermore, here it is evaluated the inclusion of the standard deviation (SD) of EC50 values in QSAR models quality...
December 13, 2017: Journal of Biomolecular Structure & Dynamics
https://www.readbyqxmd.com/read/29236075/risks-and-benefits-of-increased-nut-consumption-cardiovascular-health-benefits-outweigh-the-burden-of-carcinogenic-effects-attributed-to-aflatoxin-b%C3%A2-exposure
#16
Hanna Eneroth, Stina Wallin, Karin Leander, Johan Nilsson Sommar, Agneta Åkesson
Nuts are rich in nutrients and mounting evidence shows that consumption reduces cardiovascular disease (CVD) incidence. Nuts may also be a major source of aflatoxin B₁, a potent liver carcinogen and the risk/benefit balance is unknown. Based on national statistics and data from the PREDIMED intervention trial, we estimated the potential CVD-reduction if Swedes aged 55-79 consumed 30 g nuts/day, instead of the current national average of five grams per day. We also assessed the reduction in disability-adjusted life years (DALYs) due to myocardial infarction (MI) and stroke...
December 13, 2017: Nutrients
https://www.readbyqxmd.com/read/29220110/non-responsiveness-and-susceptibility-of-opioids-side-effects-related-to-cancer-patients-clinical-characteristics-a-post-hoc-analysis
#17
Oscar Corli, Anna Roberto, Michael I Bennett, Francesca Galli, Nicole Corsi, Eliana Rulli, Raffaella Antonione
BACKGROUND: Response to opioids is not always positive in cancer patients. A considerable proportion of patients do not respond (non-responders, NRs) or experience severe toxicity. The aim of this analysis was to assess the role of demographic characteristics, pain features, comorbidities and ongoing therapy on the lack of efficacy and on the occurrence of severe adverse drug reactions (ADRs). METHODS: This is a post-hoc analysis of a randomized controlled trial that involved 520 patients and was aimed to evaluate the efficacy and safety of four strong opioids...
December 8, 2017: Pain Practice: the Official Journal of World Institute of Pain
https://www.readbyqxmd.com/read/29219177/current-status-and-future-prospective-of-curcumin-as-a-potential-therapeutic-agent-in-the-treatment-of-colorectal-cancer
#18
REVIEW
Mohammad Jalili-Nik, Arash Soltani, Soussan Moussavi, Majid Ghayour-Mobarhan, Gordon A Ferns, Seyed Mahdi Hassanian, Amir Avan
Colorectal cancer (CRC) is the third most common cause of cancer-related deaths worldwide. Hence there is a need to identify new therapeutic agents that improve the current repertoire of chemotherapeutic drugs. The antitumor activity of curcumin has been reported for several tumors, including CRC. A recent phase I trial showed that curcumin is safe and tolerable adjunct to FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in patient-derived colorectal liver metastases at doses up to 2 grams daily...
December 8, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29214884/adjuvant-intraperitoneal-chemotherapy-for-the-treatment-of-colorectal-cancer-at-risk-for-peritoneal-carcinomatosis-a-systematic-review
#19
Paul L Feingold, Nicholas D Klemen, Mei Li M Kwong, Barry Hashimoto, Udo Rudloff
BACKGROUND: The peritoneal surface is the second most common site of disease recurrence, after the liver, following definitive surgery for colorectal cancer. Adjuvant intraperitoneal (IP) chemotherapy delivered at time of surgical resection has the potential to delay or prevent future spread to the peritoneal surface and improve clinical outcome. The exact role of adjuvant IP chemotherapy in colorectal cancer, including its associated morbidity and mortality, is not well defined. STUDY DESIGN: Systematic review and pooled random effect analysis of comparative trials examining the addition of adjuvant IP chemotherapy compared to surgery alone in colorectal cancer...
December 7, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/29212194/association-between-mir-31-3p-expression-and-cetuximab-efficacy-in-patients-with-kras-wild-type-metastatic-colorectal-cancer-a-post-hoc-analysis-of-the-new-epoc-trial
#20
Siân Pugh, Raphaële Thiébaut, John Bridgewater, Marie-Lise Grisoni, Karwan Moutasim, Francis Rousseau, Gareth J Thomas, Gareth Griffiths, François Liebaert, John Primrose, Pierre Laurent-Puig
Background: High miR-31-3p expression is associated with inferior outcomes in KRAS wild-type (WT) advanced colorectal cancer patients treated with anti-EGFR therapy. This study evaluated miR-31-3p expression in patients with operable colorectal liver metastases (LM) enrolled in the New EPOC study. Methods: MiR-31-3p expression was measured in primary tumors (PT) from 149 KRAS WT patients including 71 receiving chemotherapy alone (CT) and 78 receiving chemotherapy plus cetuximab (CTX)...
November 7, 2017: Oncotarget
keyword
keyword
28810
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"